Sling Raises $123 Million for Phase III Linsitinib
Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the 130-participant global Phase III…
